Hostname: page-component-745bb68f8f-b95js Total loading time: 0 Render date: 2025-01-13T06:49:23.002Z Has data issue: false hasContentIssue false
  • English
  • Français

Novel antioestrogens

Published online by Cambridge University Press:  05 December 2011

A. E. Wakeling  and
J. Bowler
A. E. Wakeling
Affiliation:
Research Department I, ICI Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K.
J. Bowler
Affiliation:
Research Department I, ICI Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K.
Get access

Synopsis

Recently described 7α-alkylamide analogues of oestradiol, exemplified by ICI 164,384, have the pharmacological characteristics of pure antioestrogens. ICI 164,384 is completely free of oestrogenic activity in rodents and blocks the trophic actions of exogenous and endogenous oestradiol and of partial agonist antiooestrogens like tamoxifen. In addition, ICI 164,384 is peripherally selective, producing complete involution of the uterus without affecting LH secretion in intact female rats.

In MCF-7 oestrogen-responsive, human breast cancer cells ICI 164,384 is a more potent and effective inhibitor of cell growth than tamoxifen. This difference in efficacy is reflected by a greater reduction in the proportion of cells continuing DNA synthesis in ICI 164,384-treated cultures than in tamoxifen-treated cells. This observation implies that a pure antioestrogen may provide more effective therapy of breast cancer but this will have to be demonstrated in clinical studies.

Type
Research Article
Information
Proceedings of the Royal Society of Edinburgh, Section B: Biological Sciences , Volume 95: Oestrogen and the Human Breast , 1989 , pp. 247 - 252
Copyright
Copyright © Royal Society of Edinburgh 1989

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bucourt, R., Vignau, M., Torelli, V., Richard-Foy, H., Geynet, C., Secco-Millet, C., Redeuilh, G. & Baulieu, E.-E. 1978. New biospecific adsorbents for the purification of estradiol receptor. Journal of Biological Chemistry 253, 8221–8228.Google Scholar
Cuzic, J., Wang, D. Y. & Bulbrook, R. D. 1986. The prevention of breast cancer. Lancet (i), 83–86.Google Scholar
Jackson, I. M. & Lowery, C. 1987. Clinical uses of antioestrogens. In Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action, eds Furr, B. J. A. & Wakeling, A. E., Chap. 5, pp. 87–105. Eastbourne: Bailliere Tindall.Google Scholar
Jordan, V. C. 1984. Biochemical pharmacology of antioestrogen action. Pharmacological Reviews 36, 245–276.Google Scholar
McCormack, S. & Clark, J. H. 1979. Clomid administration to pregnant rats causes abnormalities of the reproductive tract in offspring and mothers. Science 204, 629–631.Google Scholar
Musgrove, E. A., Wakeling, A. E. & Sutherland, R. L. 1988. Inhibition of proliferation of MCF-7 human breast cancer cells: similar points of action within the cell cycle of both steroidal and nonsteroidal estrogen antagonists and a calmodulin antagonist. Cancer Research (in press).Google Scholar
Nicholson, R. I. 1987. Antioestrogens and breast cancer therapy. In Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action, eds Furr, B. J. A. & Wakeling, A. E., Chap. 4, pp. 60–86. Eastbourne: Bailliere Tindall.Google Scholar
Nicholson, R. I., Gotting, K. E., Gee, J. & Walker, K. J. 1988. Actions of oestrogens and antioestrogens on rat mammary gland development: relevance to breast cancer prevention. Journal of Steroid Biochemistry 30, 95–103.CrossRefGoogle ScholarPubMed
Tucker, M. J., Adams, H. K. & Patterson, J. S. 1984. Tamoxifen. In Safety Testing of New Drugs, eds Laurence, D. R., McLean, A. E. M. & Weatherall, M., Chap. 6, pp. 125–161. London: Academic Press.Google Scholar
Wakeling, A. E. 1988. New antioestrogens without oestrogenic activity. In Endocrine Mechanisms in Cancer, ed. Cavalli, F. (in press).CrossRefGoogle Scholar
Wakeling, A. E. & Bowler, J. 1987. Steroidal pure antioestrogens. Journal of Endocrinology 112, R7–R10.Google Scholar
Wakeling, A. E. & Bowler, J. 1988a. Biology and mode of action of pure antioestrogens. Journal of Steroid Biochemistry 30, 141–147.CrossRefGoogle ScholarPubMed
Wakeling, A. E. & Bowler, J. 1988b. Novel antioestrogens without partial agonist activity. Journal of Steroid Biochemistry 31, 645–653.Google Scholar
Wakeling, A. E., Valcaccia, B., Newboult, E. & Green, L. R. 1984. Non-steroidal antioestrogens: receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. Journal of Steroid Biochemistry 20, 111–120.CrossRefGoogle ScholarPubMed
Wakeling, A. E., Newboult, E. & Peters, S. W. 1988. Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells. Journal of Molecular Endocrinology (in press).CrossRefGoogle Scholar
Weatherill, P. J., Wilson, A. P. M., Nicholson, R. I., Davies, P. & Wakeling, A. E. 1988. Interaction of the antioestrogen ICI 164,384 with the oestrogen receptor. Journal of Steroid Biochemistry 30, 263–266.Google Scholar